Newsletter · 2026-09-14 · Ashutosh Agarwal

Novo Nordisk CEO Concedes Lost Obesity Market Share to Lilly - The Obesity-Drug Pipeline - Week of September 14, 2026

The Obesity-Drug Pipeline (Issue #8) for the week of September 14, 2026. Podcast synthesis of Novo Nordisk CEO Mike Doustdar conceding lost obesity market share to Eli Lilly while touting Wegovy HD parity and a record oral-pill launch, CMS Administrator Mehmet Oz detailing most-favored-nation pricing and a $50 Medicare GLP-1 program, and Structure Therapeutics' cheap oral pill alenaglipron entering the race.

The Obesity-Drug Pipeline

Week of September 14, 2026: Novo Nordisk CEO Concedes Lost Obesity Market Share to Lilly

The single biggest development of the week: Novo Nordisk's CEO went on the record for the first time in weeks, and openly admitted Novo lost ground to Lilly.

TL;DR (15 seconds)

Novo Nordisk's CEO went on the record for the first time in weeks, and openly admitted Novo lost ground to Lilly. He conceded Lilly's Zepbound (21–22% weight loss) simply beat Novo's original Wegovy (15–16%), says Novo has now closed the gap with high-dose Wegovy HD (7.2 mg), and touted the Wegovy pill hitting 5 million prescriptions in six months, which he called "the best product launch of any pharmaceutical company to date in volume." (Power Players with Brian Sozzi)

Washington's price offensive is now the whole ballgame. CMS Administrator Dr. Mehmet Oz said 90% of branded drugs sold in America are now under "most-favored-nation" pricing, that Medicare's $50-a-month GLP-1 deal has pulled in over 600,000 people in two months (versus a $1,000+ list price), and, the number that should stop you, that Bank of America spends $250 million a year on GLP-1s just for its own employees, "up from zero" four or five years ago. (Squawk Pod)

A new oral name entered the race, and it's cheap-to-make. Structure Therapeutics reported its once-daily pill alenaglipron hit up to 16.2% weight loss at 72 weeks, squarely in injectable territory and well above Lilly's orforglipron (~11%), from a small molecule that could be mass-produced like an ordinary tablet. Phase 3 data lands in the second half of 2028. (On The Pen GLP-1 News)

How to read this issue: When a company executive or government official is speaking, we label them OPERATOR/INSIDER. Everyone else, doctors, journalists, investors, patient-advocate hosts, is commenting from the outside, so we label them ANALYST/PUNDIT and tell you their day job. This was a two-voice week for insiders: we finally got the Novo CEO on tape, and we got the man who runs Medicare and Medicaid laying out exactly how the government intends to reprice this whole category. Both matter more than the dozen clinician podcasts around them.

What's New

The five developments most likely to move numbers or the thesis, ranked by how actionable they are for a book.

1. The Novo CEO finally spoke, and it was a confession wrapped in a comeback plan. For weeks we've flagged the silence from Novo's C-suite. This week it broke. On Power Players with Brian Sozzi (September 7), Novo Nordisk's CEO, Maziar "Mike" Doustdar, the company's first non-Danish chief, a 34-year Novo veteran now about a year into the job (OPERATOR/INSIDER), did something CEOs of proud companies rarely do in public: he admitted defeat, in the past tense. "We lost market share," he said, and he explained precisely why. When Lilly came second to market, "it's easier to look at the flaws and improve." Lilly "brought a product to the market that provided 21–22% weight loss while the current version of ours at the time was 15–16%. And people felt at 21% weight loss, that's the next generation of the product… So that's the one I want. And that led into our market loss."

Then he laid out the fix, and it's a real one. First, dose: Novo launched Wegovy HD, "a 7.2 milligram of the same product, bringing the weight efficacy exactly on par with our competitor." That's the key admission for the model, Novo now claims injectable parity with Zepbound on weight, while leaning on its cardiovascular/kidney/liver label as an "almost a freebie" add-on. Second, the pill: he said the Wegovy oral version "takes 9 out of 10 patients that want a pill. One only goes to my competitor's competing pill," and that six months in, "we just announced 5 million prescriptions… that's the best product launch of any pharmaceutical company to date in volume." He even name-checked the sell side: "it was one of these Goldman notes I was reading. They acknowledge… the uptake on the pill has been strong. But… some of the street, they want to see more uptake." His retort: "90% market share is a pretty good one," and the market "sometimes is too impatient."

Two things worth flagging for the file. He put hard penetration numbers on the record: ~110 million people with obesity in the US, of whom only ~15–20 million are on any GLP-1 (branded, competitor, or compounded), and ~25 million globally, his framing for why the food-and-snack CEOs who "have not seen an impact yet" are, in his words, underestimating a timing effect, not a ceiling. And he pre-announced the pipeline: CagriSema ("semaglutide… adds amylin to it," coming "hopefully soon") plus a Novo triple-combination in the works (amylin + GIP + GLP-1) to answer Lilly's GLP/GIP/glucagon program. The read: this is a confident, numbers-heavy insider who has diagnosed the problem correctly and has the tools to fight back, but he's asking investors for patience while the gap is real and the pricing floor is dropping underneath him.

(One caveat for the skeptics: Doustdar claimed the Wegovy pill has no drug-interaction restrictions, unlike "the competing product" where "you have to think about your birth control pill… the statins… the hypertension drugs." That's a selective read, see The debate below. Both oral pills carry restrictions; they're just different ones.)

2. The man who runs Medicare just told you how this category gets repriced. This is the most important policy signal we've had all series, and it came from an insider with his hand directly on the lever. On Squawk Pod (September 8), CMS Administrator Dr. Mehmet Oz (OPERATOR/INSIDER, runs the Centers for Medicare & Medicaid Services) laid out the administration's drug-pricing machine. His claim: "90% of all… branded products sold in America are under most-favored-nation drug pricing" now, tied to "TrumpRx," with "nine more companies" coming to the Oval Office "last week." He framed it as the biggest price drop "in 63 years" and, crucially for the manufacturers, said the industry's market cap actually went up after the first round of MFN prices, because the deals also onshore roughly "100,000 jobs" and guarantee US-market access.

On GLP-1s specifically: they're "now sold to some Medicare beneficiaries under our new program at $50 a month… compared to over $1,000, which was the historical price," with "over 600,000 people who have joined this program… in the last two months." He's betting the drugs pay for themselves in avoided complications, and dropped a genuinely eye-opening private-sector data point: Bank of America's Brian Moynihan "is spending $250 million a year for GLP-1s just for his employees… And that's up from zero. Think about it, four or five years." BofA is self-insured and spends "$2 billion plus on health care a year." Oz also claimed GLP-1s are "part of the reason that for the first time in modern history, we have a decrease in obesity rates in America," and that cost data is "starting to see a downward slope" within two years.

The two-way read is sharper than ever. Bullish for volume: the government is actively subsidizing access and pushing the narrative that these drugs save money. Bearish for net price: MFN by definition drags US prices toward foreign levels (Oz said "the U.K. has already agreed to increase their prices" to meet in the middle), and every Medicare script at a $50 flat fee bypasses the commercial rebate economics. And there's a durability question the administration itself flagged: the MFN contracts "will expire after the administration completes its term" unless "Congress… codify these rules." That turns the 2026–2028 political calendar into a genuine catalyst for the group's pricing.

3. A brand-new oral contender, and it's the kind that could break the price floor. On On The Pen GLP-1 News (September 8), host Dave Knapp (ANALYST/PUNDIT, patient advocate and GLP-1 commentator) walked through fresh data from Structure Therapeutics (ticker GPCR) that deserves a slot on the fast-follower watchlist. Its lead pill, alenaglipron, a once-daily oral small-molecule GLP-1 (the same "non-peptide" category as Lilly's orforglipron), showed up to 16.2% mean weight loss at 72 weeks, with "more than one in three patients at the higher dose losing more than 20%" and, notably, "no obvious plateau" at the top doses. Knapp was honest about the mess in the data: the 45 mg cohort showed "a significant plateau and even some weight regain" pushing toward a 180 mg dose, so "more drug equals more weight loss" doesn't cleanly hold. But the headline is that an easy-to-manufacture pill is now reaching mid-teens weight loss, territory that "not very long ago" required an injection, and well above orforglipron's "around 11%."

Why an analyst cares about a pre-Phase-3 asset: the manufacturing economics. As Knapp put it, a non-peptide small molecule "changes the economics of how these drugs are manufactured, scaled and shipped." A pill "consistently reaching into the mid-teens that's just as easy to manufacture" landing in a market where entry pricing is already "a couple hundred bucks… could drive the prices lower" and widen the field of companies "capable of entering into the market." Tolerability looked manageable, a slower titration from a 2.5 mg start improved GI side effects and "fewer than 5% of participants discontinued because of adverse events." Timeline: two Phase 3 trials enrolling, topline expected in the second half of 2028. Structure also flashed an early oral amylin (ACCG-2671) with a ~6-day half-life, potentially a once-weekly pill, but on a six-person cohort where all six had nausea and vomiting, so treat that one as a science headline, not a datapoint. Net: a new credible entrant on the exact axis (cheap orals) that the bear case says compresses the whole category's pricing.

4. The oral head-to-head data is in, and it complicates Novo's "no restrictions" pitch. The oral-pill fight got real clinical grounding this week. On CME in Minutes (September 10), a Canadian primary-care education program, worth noting it "received an educational grant… from Eli Lilly, Canada", endocrinologist Dr. Sarah Stafford and family physician Dr. Vishal Patel (both ANALYST/PUNDIT, clinician-educators) reviewed Lilly's orforglipron ACHIEVE trial program. The standout: ACHIEVE-3, the head-to-head against oral semaglutide, where orforglipron came out "both non-inferior and superior" for blood-sugar lowering (12 mg orforglipron beat 7–14 mg oral semaglutide). In ACHIEVE-2, orforglipron beat the SGLT2 pill dapagliflozin on A1c (up to 1.74% vs 0.76%); in ACHIEVE-5, it added 1.5–1.8% A1c on top of insulin.

Here's the useful nuance against Doustdar's marketing. Both pills have baggage, just different kinds. Oral semaglutide (Novo's pill) has real absorption rules, take it fasted with a small sip of water and wait before eating or other meds, which is why the doctor literally advises patients to keep it "by their bedside." Orforglipron (Lilly's pill) has no food/water/timing restrictions, but it does interact via the CYP3A4 liver pathway: a simvastatin dose cap, an oral-contraceptive interaction (barrier or non-oral birth control recommended), and it's not for severe liver impairment. And separately, obesity-medicine physician Dr. Alicia Shelly (ANALYST/PUNDIT) on Back on Track (September 7) noted the birth-control caution is a class effect of GLP-1s slowing stomach emptying. So the CEO's "my pill has no restrictions" line is a stretch, his has food-timing rules; Lilly's has drug-interaction rules. Orforglipron did carry "slightly higher" GI side effects in the head-to-head, but discontinuations across all these oral studies stayed "less than 10%." For the model: orforglipron looks like the stronger oral on efficacy and convenience, but it's not the clean sweep Lilly bulls imply, and Novo's pill still owns ~90% of the oral market today.

5. Sleep apnea is quietly becoming the category's most under-modeled label. On BackTable ENT & Allergy (September 8), sleep and obesity-medicine physicians Dr. John Carter and Dr. Shanail Berry (ANALYST/PUNDIT, clinicians) put hard numbers on the obstructive sleep apnea (OSA) opportunity. Tirzepatide (Zepbound) was the first drug FDA-approved for OSA (December 2024) on the SURMOUNT-OSA trial, where ~20% weight loss drove a 55–60% reduction in the apnea-hypopnea index (roughly a 27–30-point absolute drop), enough, Carter said, to potentially "get them off CPAP… or save them from a surgery." There's a clean rule of thumb here: every 1% of weight lost yields "approximately a 2 to 2.5%" drop in apnea severity. Extend that to the triple agonists (retatrutide at 25–30% weight loss) and you're looking at a possible "65 to 70% drop in OSA severity", drugs "looking almost as good as bariatric surgery." That's a real, guideline-driven, insurable indication that expands the addressable population well beyond cosmetic weight loss, and it's one the Street rarely puts in the TAM. The catch the doctors kept returning to: affordability. Their longest continuous patient use is "about two years"; most of the multi-year users are on "three or four years of interrupted use" because the drugs are "pretty expensive" and access comes and goes.

The Debate

The bull case (steel-manned): The category leaders keep widening the moat and the market. Novo just told you, on the record, that it has closed the efficacy gap (Wegovy HD at parity with Zepbound) while keeping its cardiovascular/kidney/liver label as a differentiator, and its pill is the best-selling drug launch by volume in pharma history (5 million scripts in six months, ~90% of the oral market). Lilly's orforglipron is now proven superior head-to-head to oral semaglutide on sugar control. The government is subsidizing access, 600,000 Medicare seniors at $50/month in two months, while the CMS Administrator publicly argues the drugs save money and takes credit for the first decline in US obesity in modern history. Penetration is still a rounding error (15–20 million of 110 million obese Americans), employers like Bank of America are spending $250 million a year and treating it as an investment, and the label keeps expanding into genuinely insurable disease, sleep apnea alone (55–60% reduction in apnea severity) is a category the Street barely models.

The bear case (steel-manned): Follow the price, and every arrow points down. "Most-favored-nation" pricing now covers 90% of branded drugs and explicitly drags US prices toward the (much lower) foreign level, the UK has "already agreed" to meet in the middle, which means the US comes down. Medicare's $50 flat fee bypasses the commercial rebate model entirely, and the whole MFN scheme legally sunsets with the administration unless Congress codifies it, political risk cuts both ways. On the product side, the field is about to get crowded with cheap competition: Structure Therapeutics' alenaglipron just hit 16.2% weight loss from an easy-to-manufacture pill, the exact kind of entrant that "could drive the prices lower" and multiply the number of players. And the recurring-revenue story still leaks, clinicians report their longest continuous patient use is about two years, with most multi-year use "interrupted" by cost. Internationally, the picture is already ugly: in Ireland, Mounjaro runs €300–€420 a month private-pay (versus €1.50 for state-covered Ozempic in diabetics), the UK has restricted tirzepatide on the NHS as not cost-effective, and US list prices sit at ~$900 (Ozempic) to ~$1,400 (Wegovy), numbers that invite exactly the political repricing now underway.

My read (a framing, not a call): This was the week the pricing debate swallowed the science debate. The clinical news was incremental and favorable, parity claims, a new oral, a strong head-to-head, a bigger sleep-apnea case. But the two insider voices that actually moved the needle were both talking about price and access, not efficacy: a CEO asking for patience while his margins get squeezed, and the government official who is doing the squeezing. Notice they're not even in conflict on direction, both expect volumes to explode and per-unit economics to compress. The single number that would settle whether that's good or bad for the equities is still the one nobody hands us: net revenue per patient per year, sustained through the discontinuation drop-off. Doustdar's "5 million scripts" tells you volume is real; Oz's "$50 a month" tells you the price on a fast-growing slice of that volume is now set by Washington, not by a rebate negotiation. Watch the mix shift, not the launch headlines.

Stocks in Play

Names discussed by ticker or by name this week: LLY and NVO (both extensively), plus a new one, Structure Therapeutics (GPCR), worth adding to the watchlist. Amgen, Viking, and Roche were not named again (see Read-throughs).

Read-throughs

Fast-followers (AMGN, VKTX, Roche): still silent, but a new fast-follower gate-crashed the party. For yet another week, no podcast named Amgen's MariTide, Viking's VK2735, or Roche's CT-388/CT-996. The notable twist: the fast-follower story this week wasn't any of them, it was Structure Therapeutics, whose alenaglipron oral data (16.2%) actually cleared a meaningful bar. For a group whose entire thesis is "next-gen efficacy and buyout optionality," being lapped in the conversation by a name not even on this list is a mild negative on narrative momentum. Silence is data, and here it says attention is consolidating on the two leaders plus whoever posts a real number, and this week that was Structure, not the usual three.

Contract manufacturing / fill-finish (CTLT, LNZA, TMO): quiet, and the drift is subtly negative. No Western CDMO was named. But note the through-line in the pipeline news: the excitement is all about oral small molecules (alenaglipron, orforglipron) that are "just as easy to manufacture" as ordinary pills, a category that needs far less of the specialized sterile fill-finish and biologics capacity the injectable boom built out. If the market keeps rewarding cheap orals, the long-run capacity story for injectable-oriented CDMOs gets softer, not harder.

Pen / auto-injector suppliers (Ypsomed, Gerresheimer, Phillips Medisize): silent again, and the oral drumbeat is the headwind. No device supplier was named. Meanwhile the whole week's innovation story, Novo's pill at 5M scripts and ~90% oral share, orforglipron's head-to-head win, Structure's oral entrant, a possible once-weekly oral amylin, points away from injection hardware. The device names remain the quietest, most structurally-pressured corner of the complex.

Insurers / PBMs / employers (CVS, CI, UNH): no tickers, but the loudest policy signal of the series. No PBM was named directly. But the mechanism story is now explicit and coming from the top: MFN pricing on 90% of branded drugs, a Medicare $50 flat fee that runs around the rebate model, and the CMS Administrator openly reframing who should pay ("catching patients early… is the best interest of our government"). Every one of those routes economics away from the traditional commercial-rebate middleman. On the employer side, the narrative got a genuine counterweight this week: last week it was Starbucks and PepsiCo cutting coverage; this week it's Bank of America spending $250 million a year and treating it as an investment. The employer debate is now genuinely two-sided, which is itself new information.

Compounding / counterfeit: cooler than last week, but the safety warnings kept coming. After last week's headline Fifth Circuit ruling ending 503B mass compounding, this week was back to consumer-safety color. Dr. Alicia Shelly on Back on Track reminded listeners that compounded GLP-1s aren't FDA-regulated for contents, and, a useful fact-check for the retatrutide gray market, that retatrutide is not FDA-approved for anything in the US (Phase 3 finished, but only the type-2-diabetes results have been released, not obesity), so "any black-market retatrutide is counterfeit." Net: the legal squeeze from last week stands; this week added a reminder that the individualized/black-market fringe is still a real, and unsafe, leakage channel.

International pricing: the "commoditization" preview keeps building abroad. On The Plus SideZ (September 8), Irish obesity physician Dr. Michael Crotty (ANALYST/PUNDIT) and hosts detailed a two-tier reality: in Ireland, Ozempic is essentially free for diabetics on the state long-term-illness scheme (about €1.50/month), but Mounjaro is private-pay only at €300–€420/month (about £150 / ~€170 across the border in Northern Ireland). The UK, meanwhile, "made a decision… for tirzepatide that they would limit the availability of it on the public system" because it's "not cost efficient… unless you have very significant medical complications." Layer that onto Dr. Oz's MFN comment that the UK "has already agreed to increase their prices," and you can see the vise: foreign systems ration on cost while the US forces its prices down toward theirs.

Telehealth / DTC (read-through to Hims, Ro, LifeMD, etc.): a market-size marker worth logging. On Edge Perspectives (September 9), the direct-to-consumer GLP-1 channel was sized in passing at roughly 6.3 million yearly subscribers and about $4 billion of revenue per year across ~10 virtual metabolic-health companies, a reminder that the DTC layer is now a multi-billion-dollar business in its own right, and one squarely exposed to both the compounding crackdown and the branded self-pay pricing (e.g., Lilly Direct) that keeps undercutting it.

Medtech / bariatric: adjacent, via sleep apnea. No dedicated bariatric read-through, but BackTable's framing, triple agonists potentially matching bariatric surgery on weight loss and apnea reduction, is a slow, structural negative for surgical-weight-loss and CPAP-device volumes if the drugs keep improving. Worth keeping on the radar even though no device or hospital name was spoken.

Food / QSR: the CEO addressed it directly, and told food execs they're wrong. No food or restaurant name surfaced, but Doustdar took the question head-on: food executives say "we have not seen an impact yet," and his answer was that they're "underestimating the long-term impact" because only a small fraction of the obese population is treated so far, "a timing effect," not a no-effect. (He also flatly dismissed the old airlines-save-on-fuel trade as market noise: "Did you believe that? No, absolutely not.") For consumer-staples and QSR shorts, that's an insider explicitly telling you the demand hit is coming later, not never.

What Changed vs Last Week

Issue #7 (September 7) was dominated by two hard bull wins, the Fifth Circuit ending 503B mass compounding and Mounjaro's cardiovascular approval, landing the same week that named employers (Starbucks, PepsiCo) hardened the bear case and the Medicare $50 program got quantified. Here's the drift into this week:

The single biggest change: we finally got the Novo voice we'd been missing, and it's a new-CEO comeback narrative. For weeks we flagged "no Novo executive commentary, no Capital Markets Day." This week Doustdar spoke at length, on the record, admitting share loss and detailing the Wegovy HD parity claim, the 5-million-script pill launch, and the CagriSema/triple-combo pipeline. That's a material upgrade in signal quality on the NVO side of the book.

Policy escalated from "a Medicare program" to "a whole repricing regime." Last week the $50 program was described by a pharmacy director and a patient advocate. This week the CMS Administrator himself put it inside the much bigger TrumpRx/most-favored-nation framework, 90% of branded drugs, UK agreeing to raise prices, contracts that sunset with the administration. The policy story got both bigger and more concrete.

The employer narrative flipped to two-sided. Last week was Starbucks and PepsiCo cutting coverage. This week is Bank of America spending $250 million a year on GLP-1s for employees, framed as an investment. The bull now has a marquee-employer datapoint of its own.

A genuinely new pipeline name entered: Structure Therapeutics (GPCR). Last week's pipeline focus was retatrutide, orforglipron, CagriSema, oral semaglutide. This week added alenaglipron (16.2% oral) and an early oral amylin, a fresh cheap-orals threat that speaks directly to the bear's pricing thesis.

Confirmed / extended: The penetration story got the CEO's own numbers (110M obese in the US, 15–20M treated, ~25M globally), consistent with last week's "one in five households" framing but now sourced to the manufacturer. The $50 Medicare enrollment held (600,000+, now framed as "in the last two months"). The persistence problem sharpened from a different angle: clinicians this week put the ceiling on continuous use at about two years, with the rest "interrupted" by cost. Retatrutide's regulatory status (not approved, obesity data not released) was reconfirmed. Oral-vs-injectable efficacy (12–15% pill vs 17–18% injection for semaglutide) held.

New this week: Wegovy HD (7.2 mg) parity claim; the "5 million scripts / best launch ever" pill number; orforglipron's ACHIEVE-3 head-to-head win and the full restriction profile of both oral pills; the SURMOUNT-OSA specifics (55–60% AHI reduction) and the "1% weight = 2–2.5% AHI" rule; STEP-YOUNG pediatric data (40.4% of children 6–11 moved below the obesity threshold at 68 weeks vs 0% placebo); the Structure Therapeutics data; Ireland/UK pricing specifics; and the DTC market-size marker (6.3M subscribers, ~$4B/year).

Still quiet (zero dedicated coverage): Amgen MariTide, Viking VK2735, Roche CT-388/CT-996 (now a long, conspicuous multi-week gap); UBT-251; Western CDMOs (CTLT, LNZA, TMO) and pen/injector suppliers (Ypsomed, Gerresheimer, Phillips Medisize) by name; named PBMs (CVS, CI, UNH); the Tennessee Fair Rx Act and other named state statutes (last week had CalRx; nothing this week); and most label-expansion trials by name, SELECT, SUMMIT, ESSENCE, FLOW, and STEP-HFpEF were absent, though SURMOUNT-OSA got real airtime and MASH/liver was touched generically. And, every week, the missing dataset that would end the whole fight: clean TRx/NRx counts times a real net price per script.

The honest summary: last week the bull side won on courts and labels; this week the story moved to price and access, and both insider voices, a squeezed CEO and the official doing the squeezing, were talking about exactly that. Volume is compounding (5 million scripts, 600,000 Medicare sign-ups); price is being actively pushed down (MFN on 90% of drugs, $50 flat fees, a new cheap-orals entrant). Same elephant, and this week you could hear it repricing.